Point of Care (POC) Genetic Testing Market

• In August 2022, Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostic products, announced its agreement to acquire all outstanding shares of Curiosity Diagnostics, Sp. Z. o. o. from Scope Fluidics, S.A., a Warsaw, Poland-based developer of innovative technology solutions for the medical diagnostics and healthcare markets.

• In January 2023, Cipla Ltd. launched Cippoint, a point-of-care testing device capable of identifying a wide range of health conditions, including cardiac markers, diabetes, infectious diseases, fertility, and thyroid function.

In this report, the POC Genetic Testing Market has been segmented by Product Type, Test Type, Application, End User, and Geography.

POC Genetic Testing Market, Segmentation by Product Type

The POC Genetic Testing Market has been segmented by Product Type into POCT Cancer Kits, Molecular POC Kits, POCT in Antibiotic Therapies, and Assay Cartridge.

POCT Cancer Kits

POCT cancer kits are gaining rapid traction due to their ability to provide immediate genetic insights for oncology applications. These kits enable early cancer detection and personalized treatment planning at the point of care. Their integration with biomarker-based diagnostics improves clinical decision-making. Growing cancer incidence and demand for non-invasive testing are key growth drivers in this segment.

Molecular POC Kits

Molecular POC kits offer high sensitivity and specificity for detecting gene-level mutations and abnormalities. These kits are used across various disease categories, including infectious diseases and inherited disorders. Their portability makes them ideal for use in low-resource or decentralized healthcare settings. Advances in microfluidics and nucleic acid amplification continue to propel market adoption.

POCT in Antibiotic Therapies

This segment supports rapid pathogen identification and resistance gene detection, enabling effective antibiotic use. Genetic tests for antibiotic stewardship help clinicians reduce unnecessary prescriptions and combat resistance. The growing global concern over antimicrobial resistance (AMR) boosts demand for this solution. Clinical settings are integrating these tools into routine infectious disease management.

Assay Cartridge

Assay cartridges are used in conjunction with portable devices to perform rapid nucleic acid detection at the point of care. Their self-contained design allows for automated, contamination-free processing. This format is preferred for multiplex testing and reducing user error. As demand for compact diagnostic workflows rises, assay cartridge usage is expected to grow significantly.

POC Genetic Testing Market, Segmentation by Test Type

The POC Genetic Testing Market has been segmented by Test Type into Carrier Testing, Diagnostic Testing, Predictive & Presymptomatic Testing, Prenatal Testing, Newborn Screening, and Others.

Carrier Testing

Carrier testing identifies individuals carrying genetic variants that may be passed to offspring, making it vital for reproductive decision-making. POC solutions allow for faster turnaround and on-site genetic counseling. Demand is increasing due to the rising emphasis on preconception health. These tests are widely applied in communities with known inherited disorders.

Diagnostic Testing

Diagnostic genetic testing at the point of care enables real-time identification of specific genetic conditions. These tests reduce delays in diagnosis and help initiate immediate treatment protocols. Especially in rare or hard-to-diagnose diseases, rapid results provide critical clinical value. Integration into urgent care settings is expanding accessibility and adoption.

Predictive & Presymptomatic Testing

These tests assess the risk of developing genetic diseases before symptoms appear, aiding in preventive healthcare strategies. With POC capabilities, patients can access risk information on-site, improving early intervention. This segment is particularly important for diseases like Huntington’s or BRCA-related cancers. Awareness of proactive genetics continues to drive market growth.

Prenatal Testing

Prenatal POC tests allow for early detection of chromosomal abnormalities such as Down syndrome. Non-invasive formats and real-time genetic screening are appealing to both patients and providers. These tests reduce anxiety and help in making informed pregnancy management decisions. Advances in microfluidic and cell-free DNA tech are accelerating adoption.

Newborn Screening

POC newborn genetic screening helps detect metabolic and hereditary disorders soon after birth. Immediate intervention is crucial for avoiding long-term health complications. These tests improve neonatal outcomes and reduce hospital stays. Governments in developed and emerging economies are increasingly integrating such tests into national health programs.

Others

This category includes nutrigenomics, pharmacogenomics, and other specialized test types used in lifestyle or personalized medicine. These POC solutions are helping consumers and clinicians make gene-based decisions in real-time. Increasing interest in wellness genomics and chronic disease prevention is expanding the range of applications. As technology becomes more affordable, this segment is poised to grow.

POC Genetic Testing Market, Segmentation by Application

The POC Genetic Testing Market has been segmented by Application into Drug Discovery & Research, Treatment Analysis, and Diagnosis.

Drug Discovery & Research

POC genetic testing is revolutionizing early-phase clinical research by enabling faster sample-to-data workflows. Researchers benefit from on-site genotyping capabilities, reducing study timelines. Its use in identifying targetable genetic mutations enhances the value of precision drug development. Pharma and biotech firms are incorporating these tools into clinical trial frameworks.

Treatment Analysis

This segment supports personalized treatment planning by linking genetic variants to therapeutic outcomes. POC platforms help clinicians assess drug metabolism genes and predict treatment efficacy or adverse reactions. Oncology, psychiatry, and cardiology are major fields adopting this capability. The focus on pharmacogenomics at the bedside continues to expand its use.

Diagnosis

Diagnostic applications dominate due to the role of POC testing in rapid disease identification. These tests are essential in low-resource settings where central lab access is limited. Faster diagnostic decisions translate to improved clinical workflows and patient satisfaction. Conditions like genetic anemia, cystic fibrosis, and mitochondrial diseases benefit from this segment.

POC Genetic Testing Market, Segmentation by End User

The POC Genetic Testing Market has been segmented by End User into Research Laboratory, Diagnostic Labs, Bio-Pharmaceutical Industry, and Academic Institutions.

Research Laboratory

Research laboratories utilize POC genetic testing to enhance study accuracy and reduce time to data. The ability to perform on-demand testing accelerates innovation in genomics. Integration with portable PCR and sequencing platforms is becoming standard. Collaborations with biotech startups are increasing deployment across academic research ecosystems.

Diagnostic Labs

Diagnostic labs implement POC testing to offer quicker turnaround for patients requiring urgent results. Their role in community and outpatient testing continues to grow. Labs prefer solutions that combine throughput with high precision and minimal processing time. Market adoption is strengthened by reimbursement policies supporting genetic screening.

Bio-Pharmaceutical Industry

Bio-pharma companies are leveraging POC platforms in clinical trials to identify genetic markers that influence treatment responses. These tools support patient stratification, enhancing drug development success rates. Real-time data collection improves regulatory compliance and trial efficiency. This segment benefits from long-term R&D investments in precision medicine.

Academic Institutions

Academic institutions incorporate POC testing into curriculum and hands-on training for next-gen medical professionals. Research applications include gene expression studies, SNP analysis, and epigenetics. These users often drive innovation and validation of novel point-of-care devices. The growing emphasis on translational research further boosts institutional adoption.

POC Genetic Testing Market, Segmentation by Geography

In this report, the POC Genetic Testing Market has been segmented by Geography into North America, Europe, Asia Pacific, Middle East & Africa, and Latin America.

Point-Of-Care Genetic Testing Market Share (%), by Geographical Region

North America

North America dominates the market with an estimated share of 36%, driven by high healthcare spending and early technology adoption. The U.S. leads in terms of regulatory approvals and presence of advanced diagnostic players. Rising focus on personalized medicine and direct-to-consumer genetics drives growth. Continuous funding for genetic research also supports expansion.

Europe

Europe holds around 27% of the market share, supported by government-backed genomics programs and patient advocacy groups. Countries like the UK and Germany are leading adopters. The region benefits from a well-established regulatory framework and growing public awareness. Investment in clinical genomics infrastructure is accelerating adoption across healthcare systems.

Asia Pacific

Asia Pacific represents about 21% of the global share, driven by rising demand in countries like China, India, and Japan. Expanding access to affordable genetic testing and the growth of mobile health are key drivers. Public-private partnerships are improving diagnostic capabilities. The region is emerging as a manufacturing hub for cost-effective POC devices.

Middle East & Africa

This region contributes approximately 9% of the market, with UAE and South Africa spearheading genomic innovation. Efforts to improve rural healthcare delivery are boosting adoption. The lack of central labs in remote areas drives demand for mobile testing technologies. Awareness campaigns around hereditary diseases support long-term growth.

Latin America

Latin America holds a 7% share, led by Brazil, Mexico, and Argentina. Increasing demand for genetic carrier screening and newborn testing is driving growth. Regional governments are investing in public health genomics initiatives. However, disparities in access and affordability remain barriers that industry players aim to address.

This report provides an in depth analysis of various factors that impact the dynamics of Global Point-Of-Care Genetic Testing Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunity Analysis

Key players in Global Point-Of-Care Genetic Testing Market include,

• Cepheid
• IQuum
• Biocartis
• Abbott
• Idaho Technologies
• ThermoFisher
• Roche
• Optigene
• Lumora

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis